Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: A cost-effectiveness analysis

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: A cost-effectiveness analysis

BACKGROUND: Age-related macular degeneration (AMD) is a leading cause of blindness worldwide and is the most common cause of blindness in developed countries. Despite antivascular endothelial growth factor (anti-VEGF) therapy demonstrating improvements in visual and anatomical outcomes, unmet needs...

Full description

Bibliographic Details
Main Authors: Agashivala, N. (Author), Carlton, R. (Author), Hassan, T. (Author), Wykoff, C.C (Author), Yu, J.S (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
adolescent
Adolescent
adult
Adult
aflibercept
angiogenesis inhibitor
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Article
best corrected visual acuity
brolucizumab
cohort analysis
controlled study
cost benefit analysis
cost effectiveness analysis
Cost-Benefit Analysis
Cross-Sectional Studies
cross-sectional study
drug cost
drug efficacy
drug safety
economics
female
Female
fluorescence angiography
fusion protein
human
Humans
major clinical study
male
Male
Markov chain
middle aged
Middle Aged
monoclonal antibody
mortality rate
phase 3 clinical trial
quality adjusted life year
randomized controlled trial
ranibizumab
Ranibizumab
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins
sensitivity analysis
treatment duration
unspecified side effect
vasculotropin receptor
visual acuity
Visual Acuity
visual impairment
wet macular degeneration
Wet Macular Degeneration
young adult
Young Adult
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items